伊布替尼治疗首次复发套细胞淋巴瘤:英国211例真实世界分析
该多中心回顾性分析纳入英国国家医疗服务体系内211例首次复发的套细胞淋巴瘤患者,中位年龄73岁,接受伊布替尼二线治疗。10%患者因药物相关不良事件减量,5%停药。
要点
- 伊布替尼二线治疗首次复发套细胞淋巴瘤总缓解率69%,完全缓解率27%。
核心结论
- 真实世界中伊布替尼用于首次复发套细胞淋巴瘤具有临床获益且耐受性良好。
- 伊布替尼进展后患者生存有限,但部分患者接受R-BAC方案结局有希望。
研究设计与样本
- 多中心回顾性分析,纳入英国国家医疗服务体系内211例复发/难治套细胞淋巴瘤患者,中位年龄73岁,接受伊布替尼二线治疗。
主要发现
- 总缓解率69%,其中完全缓解27%。
- 药物相关不良事件导致10%患者减量,5%患者停药。
- 152例停用伊布替尼的患者中100例为疾病进展,其中43%接受了后续系统性治疗。
临床怎么用
- 伊布替尼可作为首次复发套细胞淋巴瘤的二线治疗选择,需关注不良事件管理。
- 伊布替尼进展后可考虑R-BAC等后续系统性治疗,但需个体化评估。
局限性
- 回顾性设计可能存在选择偏倚和信息偏倚。
- 真实世界人群异质性较大,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when given second line in a real-world setting. Our multicentre retrospective analysis included 211 R/R MCL patients, median age 73 years, receiving ibrutinib second-line within the United Kingdom's National Health Service. Overall response to ibrutinib was 69% (complete response 27%). The median progression-free survival (PFS) was 17·8 months (95% CI 13·1-22·2) and median overall survival (OS) 23·9 months (95% CI 15·0-32·8). Drug-related adverse event led to dose reduction in 10% of patients and discontinuation in 5%. In patients with progressive disease, accounting for 100 of 152 patients stopping ibrutinib, 43% received further systemic therapy. Post-ibrutinib rituximab, bendamustine and cytarabine (R-BAC) showed a trend toward improved survival compared to alternative systemic treatments (post-ibrutinib median OS 14·0 months, 95% CI 8·1-19·8, vs. 3·6 months, 95% CI 2·6-4·5, P = 0·06). Our study confirms the clinical benefit and good tolerability of ibrutinib at first relapse in a real-world population. Patients progressing on ibrutinib had limited survival but outcomes with R-BAC in select patients were promising.
引用
- McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol. 2021. PMID: 33620106. doi:10.1111/bjh.17363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。